Anti-CTLA-8/IL-17a Antibody (Vunakizumab)
Catalog No.
F1298
Anti-CTLA-8/IL-17a Antibody (Vunakizumab)
Featured Products
Vunakizumab (Anti-Human IL17A Recombinant Antibody) is a recombinant humanized IgGκ monoclonal antibody that targets IL-17A and inhibits its interaction with the IL-17 receptor. Vunakizumab can be used to study autoimmune diseases such as psoriatic arthritis, ankylosing spondylitis, multiple sclerosis, and inflammatory arthritis.
Quality Control & DataSheet
- View current batch:
-
Purity > 95% by SDS-PAGE and SEC-HPLC analyses.
- MSDS (Material Safety Data Sheet)
- Datasheet
146.38 kDa
Dry ice
1792181-33-9
-80°C
2 years
Liquid
See label
For reconstitution, we recommend adding sterile, distilled water to achieve a final antibody concentration. Gently shake it to solubilize the protein completely. Do not vortex.
CHO
SHR 1314, SHR-1314, SHR1314
100 mM Pro 20 mM Arg pH 5.0. No preservative!
Q16552
Human
Unconjugated
Monoclonal
Protein A
IgG1
ELISA, FACS, Kinetics, Functional assay, Animal Model
CTLA-8 / IL-17a
Please avoid freeze-thaw cycles.